Data shown is for informational purposes only and does not constitute investment advice. TopFund is not SEBI-registered. Consult a SEBI-registered advisor before investing.
Gaudium IVF IPO
Price Band
₹75.0–79.0
Issue Size
₹165.0 Cr
Lot Size
189 shares
Min Investment
₹14,931
GMP
—
Issue Price
₹79.0
Gaudium IVF IPO AI Summary
- Gaudium IVF IPO is listed on BSE, NSE in the Healthcare Service Provider sector.
- Price band: ₹75.0–₹79.0 per share, lot size 189 shares (min. investment ₹14,931).
- Subscription window: 20 Feb–24 Feb 2026, listing on 27 Feb 2026.
Gaudium IVF is a leading fertility care provider in India with a wide range of services and a strong operational model. The IPO aims to raise funds for expansion and debt repayment, reflecting the company's growth strategy in the healthcare sector.
TopFund is not SEBI-registered — this is educational analysis, not personalized investment advice.
Important Dates
Subscription Status
Subscription data unavailable
Gaudium IVF IPO Grey Market Premium (GMP) Today
GMP not available yet
Grey Market Premium is updated daily. Check back closer to the listing date.
About the Company
Gaudium IVF and Women Health Limited is an India-based fertility care provider specializing in In Vitro Fertilization (IVF) and related reproductive treatments. The company operates through a hub-and-spoke model and has expanded its presence across multiple states, with more than thirty centers comprising seven main hubs and twenty-eight spoke clinics. It has also formed strategic partnerships with infertility experts to increase awareness and access to Assisted Reproductive Technology (ART) and IVF services. Gaudium serves both domestic and international patients from countries such as Canada, the United Kingdom, the United States, Kenya, South Africa, and Oman. Its key centers are located in major cities including Delhi (Janakpuri and Kailash Colony), Mumbai (Khar West), Ludhiana, Srinagar, Patna, and Bangalore. The company provides a wide range of fertility treatments, including IVF, ICSI, IUI, and ovulation induction, addressing infertility challenges in both men and women. It also offers gynecological care for conditions such as PCOS/PCOD and endometriosis, along with specialized management for high-risk pregnancies. Additionally, the centers provide advanced male infertility treatments, including specialized sperm retrieval procedures. Key strengths: A strong patient-focused care model An experienced and skilled medical team Advanced INTEGRA Ti laboratories for ICSI procedures Highly technical ultrasound-guided services Strategically located central hubs in major urban areas An asset-light operating structure
Company Financials (₹ Cr)
As of 2025-09-30
| Period Ended | 30 Sep 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 106.62 | 88.51 | 51.01 | 36.63 |
| Total Income | 49.75 | 70.96 | 48.15 | 44.26 |
| Profit After Tax | 12.51 | 19.13 | 10.32 | 13.53 |
| EBITDA | 18.95 | 28.63 | 19.27 | 20.07 |
| NET Worth | 58.85 | 46.30 | 26.99 | 22.73 |
| Reserves and Surplus | 28.16 | 15.60 | 26.00 | 21.74 |
| Total Borrowing | 22.51 | 18.93 | 15.73 | 9.78 |
Key Ratios
EPS
₹3.12
NAV
₹7.54
ROE
41.31%
ROCE
39.70%
RoNW
41.71%
P/B Value
10.48
P/E Ratio
25.36
Market Cap
₹575.02 Cr
PAT Margin
26.96%
Debt/Equity
0.41
Promoters
Manika Khanna, Peeyush Khanna and Vishad Khanna
Objects of the Issue
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects: # Issue Objects Est Amt (₹ Cr.) 1 Funding capital expenditure towards establishment of New IVF Centers of the Company. 50.00 2 Repayment/pre-payment, in full or in part, of certain outstanding loans availed by the Company. 20.00 3 General Corporate Purposes 12.28 4 Issue Expenses 14.15 Total 96.43
IPO Evaluation
Generated 23 Sep 2026Revenue Trend
Total Income was ₹44.26 Cr in the year ending 31 Mar 2023, increasing to ₹48.15 Cr by 31 Mar 2024. This figure rose further to ₹70.96 Cr by 31 Mar 2025, before declining to ₹49.75 Cr by 30 Sep 2025, though this is a 9-month figure, not a full year, so isn't directly comparable.
Profit Trend
Profit After Tax was ₹13.53 Cr in the year ending 31 Mar 2023, increasing to ₹10.32 Cr by 31 Mar 2024. It then rose to ₹19.13 Cr by 31 Mar 2025, before decreasing to ₹12.51 Cr by 30 Sep 2025, though this is a 9-month figure, not a full year, so isn't directly comparable.
Grey Market Premium, Explained
The Grey Market Premium (GMP) refers to the unofficial market where shares of an IPO are traded before they are listed on the stock exchange. A positive GMP indicates strong demand for the IPO, while a negative GMP suggests weak demand. However, GMP is not a guarantee of listing day performance.
Who This IPO Suits
Investors comfortable with short-term volatility and a long-term horizon typically weigh IPOs like this against their investment goals and risk tolerance. It's important to consider the company's growth potential and market conditions before deciding.
Who May Want to Wait
Investors who are risk-averse or prefer stable, established companies may want to avoid IPOs like this, which can be subject to high volatility and uncertainty in their early trading days.
IPO Timeline, Explained
The IPO process includes several key dates: the opening date for subscription is on 20 February 2026, and it closes on 24 February 2026. Allotment of shares will be done on 25 February 2026, with the listing date set for 27 February 2026.
Listing Gains — The Risk
Listing day gains can be unpredictable and depend on various factors, including overall market conditions and investor sentiment. While some IPOs may experience significant gains on their first day of trading, others may not perform as well, leading to potential losses for investors.
This evaluation is generated from Gaudium IVF's own public IPO filing data for educational purposes and is not investment advice or a recommendation to apply, subscribe to, or avoid this issue — see Broker Recommendations below for named third-party research views (clearly attributed, not TopFund's own). TopFund is not a SEBI-registered investment adviser — see our Disclaimer.
Frequently Asked Questions
What is the price band of Gaudium IVF IPO?
The price band of Gaudium IVF IPO is ₹75.0–₹79.0 per share.
When does Gaudium IVF IPO open and close?
Gaudium IVF IPO opens on 20 February 2026 and closes on 24 February 2026.
When does Gaudium IVF IPO list on the stock exchange?
Gaudium IVF IPO listed on 27 February 2026 at ₹79.0.
What is the lot size for Gaudium IVF IPO?
The lot size for Gaudium IVF IPO is 189 shares, requiring a minimum investment of ₹14,931.
What is the price band for the Gaudium IVF IPO?
The price band for the Gaudium IVF IPO is ₹75.0 to ₹79.0.
What is the minimum investment amount for this IPO?
The minimum investment amount for this IPO is ₹14,931.
What is the lot size for the Gaudium IVF IPO?
The lot size for this IPO is 189 shares.
When is the listing date for Gaudium IVF?
The listing date for Gaudium IVF is 27 February 2026.
What does GMP mean?
GMP stands for Grey Market Premium, which indicates the expected premium of the IPO shares in the grey market before they are officially listed.
Issue Details
Investor Allocation
Registrar
Lead Managers / Book Running
IPO Timeline
Open
20 Feb 2026
Close
24 Feb 2026
Allotment
25 Feb 2026
Listing
27 Feb 2026
Similar IPOs in Healthcare Service Provider
Plan Your IPO Investment
Related Articles
Community Sentiment
What are other investors planning for Gaudium IVF?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
No comments yet — start the discussion.